NL-OMON30253尚未招募3 期
Treatment of recurrent Clostridium difficile infection with fecal therapy: the FECAL trial (Fecal enema to Eliminate Clostridium difficile Associated Longstanding diarrhea) - FECAL trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients who once have been treated with proper antibiotics for positieve C. difficile associated diarrhee and now presenting with recurrence of diarrhee can be included in our study.
排除标准
- •Patients with limited life-expectancy (less than 3 months) are excluded from study participance. Feces donor subjects will be selected form healthy relatives and friends and will be thoroughly screened on contagious diseases in blood and feces.
研究者
相似试验
已完成
不适用
Clostridium difficile - adjuvant therapy with high dose VSL#3® will shorten hospital stay and reduce relapse rates in Clostridium difficile associated diarrhoeaISRCTN57305201niversity Hospitals Bristol NHS Foundation Trust (UK)114
招募中
不适用
Clinical aspects of Clostridium difficile infection after initiation of anti tuberculous medicatioCertain infectious and parasitic diseasesKCT0000808Konyang University Hospital50
招募中
不适用
The FECAL trial, Fecal therapy to Eliminate Clostridium difficile Associated Longstanding diarrhoea.1. Clostridium difficile<br />2. Recurrent (NLD: recidiverend)<br />3. antibiotic associated diarrhoea<br />4. diarrhoea (NLD: diarree)<br />5. feces (NLD: ontlasting)<br />6. transplantation (NLD: transplantatie).NL-OMON25892Academic Medical Center Amsterdamthe Netherlands120
尚未招募
不适用
A prospective study of Clostridium difficile infection and quality improvement initiative based on automatic CVRCertain infectious and parasitic diseasesKCT0005892The Catholic University of Korea, Bucheon St. Mary's Hospital200
进行中（未招募）
不适用
Treatment in patients with recurrent infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response. - Treatment of IgG Subclass Deficiency and/or Deficiency of Anti-Polysaccharide Antibody ResponseEstablished diagnosis of IgG subclass deficiency, and/or (selective) antipolysaccharide antibody deficiency.MedDRA version: 8.1Level: LLTClassification code 10021275Term: IgG subclass deficiencyEUCTR2006-005215-98-NLSanquin Plasma Products